^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    YT-19/22

    i
    Other names: YT-19/22, CD19/CD22-Dual-STAR-T
    Associations

    News

    Trials
    Company:
    BriSTAR Immunotech
    Drug class:
    CD19 inhibitor, CD22 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2years
    CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL) (clinicaltrials.gov)
    P1, N=2, Terminated, Hebei Yanda Ludaopei Hospital | N=12 --> 2 | Trial completion date: Dec 2022 --> May 2022 | Suspended --> Terminated | Trial primary completion date: Oct 2022 --> May 2022; Adjustment plan
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    cyclophosphamide • YT-19/22
    almost3years
    CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL) (clinicaltrials.gov)
    P1, N=12, Suspended, Hebei Yanda Ludaopei Hospital | Recruiting --> Suspended
    Trial suspension
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    YT-19/22
    over3years
    CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL) (clinicaltrials.gov)
    P1, N=12, Recruiting, Hebei Yanda Ludaopei Hospital | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    YT-19/22
    over4years
    CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL) (clinicaltrials.gov)
    P1; N=12; Not yet recruiting; Sponsor:Hebei Yanda Ludaopei Hospital
    New P1 trial • Clinical
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    YT-19/22